The serological diversity of serum IgG/IgA/IgM against the SARS-CoV-2 nucleoprotein, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan

Kaneko, Yoshihiko; Sugiyama, Akira; Tanaka, Toshiya; Fukui, Kazushige; Taguchi, Azuma; Nakayama, Aya; Koga, Kazumasa; Kishi, Yoshiro; Wang, Da-Ming; Xia, Fuzhen; He, Fan; Zheng, Liang; Yu, Yizhen; Wada, Yuji; Wada, Yoshiaki; Kodama, Tatsuhiko; Kawamura, Takeshi

doi:10.1101/2021.06.17.21258858

Cited by 3 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To investigate the kinetics of antibody production against SARS-CoV-2, we measured the levels of immunoglobulin G (IgG) specific for the S1 subunit of S protein (IgG-S1) using iFlash 3000 chemiluminescence immunoassay analyzer (Shenzhen YHLO Biotech, China;) [9] and IgG specific for full-length S protein (anti-Spike IgG) using conventional ELISA [3]. According to the instructions, results with values ≥ 10 arbitrary units (AU)/mL for IgG-S1 and with values ≥ 0.087 OD 450 nm for anti-Spike IgG were considered positive.…”

Section: Case Reportmentioning

confidence: 99%

A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection

et al. 2022

View full text Add to dashboard Cite

Hemodialysis patients are vulnerable to severe and lethal COVID-19, and their protective immunity against COVID-19 is not yet fully understood. Therefore, we report a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and discuss the role of antibodies in SARS-CoV-2 infection. A hemodialysis patient developed asymptomatic COVID-19 due to an outbreak in a hospital on October 29th, 2020. As he was hospitalized and did not develop any symptoms, he was discharged on November 9th. On January 18th, he presented with symptomatic COVID-19 due to close household contact. Then, he developed respiratory failure and was transferred to National Center for Global Health and Medicine if he would need intensive care. He recovered with oxygen inhalation, favipiravir, and steroid treatment, and was discharged on February 12th. To evaluate anti-SARS-CoV-2 antibodies during two hospital stays, we measured immunoglobulin (Ig) G specific for S1 subunit of Spike (S) protein of SARS-CoV-2 (IgG-S1) , IgG specific for the full-length S protein (anti-Spike IgG) and neutralizing antibodies. No seroconversion occurred 5 days after initial infection, the seroconversion of IgG-S1 was observed 10 days after the second infection. Similar to IgG-S1 antibody titer results, anti-Spike IgG and neutralizing antibodies increased from 12 days after the second infection. In conclusion, we experienced a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and showed the kinetics and role of antibodies in SARS-CoV-2 infection. Further studies are needed to understand SARS-CoV-2 reinfection risk in hemodialysis patients and its clinical significance.

show abstract

Section: Case Reportmentioning

confidence: 99%

A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection

et al. 2022

View full text Add to dashboard Cite

show abstract

Hemodialysis patients with coronavirus disease 2019: reduced antibody response

et al. 2021

View full text Add to dashboard Cite

Background Because patients on maintenance hemodialysis (HD) have an impaired immune response to pathogens, they are at higher risk of severe coronavirus disease 2019 (COVID-19). However, data on antibody production among HD patients with COVID-19 is scarce. Thus, we performed a retrospective cohort study evaluating severe acute respiratory syndrome coronavirus two antibody (SARS-CoV-2) production within 1 month after COVID-19 onset in hospitalized patients on HD. Methods SARS-CoV-2-specific immunoglobulin (Ig) G levels were quantified using an iFlash 3000 Chemiluminescence Immunoassay analyzer (Shenzhen YHLO Biotech Co., Ltd.) to detect IgG antibodies specific for the S1 subunit of the spike protein (IgG-S1). Propensity score matching was used to balance covariate distribution in HD and non-HD patients. From April 2020 to February 2021, antibody testing was performed on 161 hospitalized patients with symptomatic COVID-19. Of them, 34 HD patients were matched to 68 non-HD patients. Results After propensity score matching, the median levels of IgG-S1 in the HD patients at 7–13 days after symptom onset were significantly lower than in non-HD patients, especially in those with severe disease. Among all patients, those with severe disease produced lower levels of IgG-S1 at 7–13 days compared with non-severe patients. Conclusion COVID-19 patients with severe disease, especially those undergoing HD, had lower IgG-S1 production in the second week of the disease. Thus, the increased risk of severe COVID-19 in HD patients may be, in part, due to a slow and reduced antibody response.

show abstract

Serologic Survey of IgG Against SARS-CoV-2 Among Hospital Visitors Without a History of SARS-CoV-2 Infection in Tokyo, 2020–2021

Sanada

Honda

Yasui

et al. 2022

Journal of Epidemiology

Self Cite

View full text Add to dashboard Cite

The serological diversity of serum IgG/IgA/IgM against the SARS-CoV-2 nucleoprotein, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan

Cited by 3 publications

References 22 publications

A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection

A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection

Hemodialysis patients with coronavirus disease 2019: reduced antibody response

Serologic Survey of IgG Against SARS-CoV-2 Among Hospital Visitors Without a History of SARS-CoV-2 Infection in Tokyo, 2020–2021

Contact Info

Product

Resources

About